Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company’s promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms. The company is expected to report its second-quarter earnings in the coming weeks. While Viking Therapeutics’ stock price has recently pulled back from its 52-week high, investors are still optimistic about its potential. Analysts believe that Viking’s oral weig…